Breast Cancer Diagnosed by Measuring Circulating Tumor DNA
By LabMedica International staff writers Posted on 07 Aug 2017 |
Image: A cluster of circulating tumor cells (CTCs, shown in red) originated from the blood of a breast cancer patient (Photo courtesy of the NIH).
An unintended consequence of a recent drug study was the discovery that measurement of circulating tumor DNA (ctDNA) could be used to diagnose a type of breast cancer with an unamplified HER2 mutation.
HER2 is a member of the human epidermal growth factor receptor family. Amplification, over-expression, or a mutation of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.
Investigators at Baylor College of Medicine (Houston, TX, USA) conducted a single arm phase II trial to assess the clinical benefit rate of the drug neratinib, a dual inhibitor of Her2 and epidermal growth factor receptor (EGFR) in HER2-mutated non-amplified metastatic breast cancer. Neratinib blocks the action of its target proteins by covalently binding to a cysteine side chain.
To conduct the study, the investigators required biopsy material from the tumor in order to determine the presence of the HER2 mutation. However, this proved to be a major difficulty, as 20 to 30% of the patients could not provide sufficient material to make the diagnosis.
In contrast, baseline ctDNA sequencing identified the same HER2 mutation in 11 of 14 tumor positive cases and correctly assigned 32 of 32 informative negative cases. Additionally, ctDNA HER2-mutant variant allele frequency decreased in nine of 11 paired samples at week four, followed by an increase upon progression.
"To assist in our ability to identify patients with HER2 mutation-positive tumors, we conducted circulating tumor DNA analysis," said senior author Dr. Matthew Ellis, professor of oncology at Baylor College of Medicine. "The tumor's DNA is released into the human bloodstream, and we were able to determine the presence of the mutation in blood samples from the patients. Importantly the circulating tumor DNA results were highly concordant with the tumor sequencing results, and they were much easier to determine. Notably, the blood test was sensitive enough that we could use it as a tool to determine eligibility for the clinical trial. A circulating tumor DNA-based blood test also could therefore be potentially used to monitor tumor progression and to determine whether patients are responding or not to treatment after just one month of therapy."
The study was published in the July 5, 2017, online edition of the journal Clinical Cancer Research.
Related Links:
Baylor College of Medicine
HER2 is a member of the human epidermal growth factor receptor family. Amplification, over-expression, or a mutation of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.
Investigators at Baylor College of Medicine (Houston, TX, USA) conducted a single arm phase II trial to assess the clinical benefit rate of the drug neratinib, a dual inhibitor of Her2 and epidermal growth factor receptor (EGFR) in HER2-mutated non-amplified metastatic breast cancer. Neratinib blocks the action of its target proteins by covalently binding to a cysteine side chain.
To conduct the study, the investigators required biopsy material from the tumor in order to determine the presence of the HER2 mutation. However, this proved to be a major difficulty, as 20 to 30% of the patients could not provide sufficient material to make the diagnosis.
In contrast, baseline ctDNA sequencing identified the same HER2 mutation in 11 of 14 tumor positive cases and correctly assigned 32 of 32 informative negative cases. Additionally, ctDNA HER2-mutant variant allele frequency decreased in nine of 11 paired samples at week four, followed by an increase upon progression.
"To assist in our ability to identify patients with HER2 mutation-positive tumors, we conducted circulating tumor DNA analysis," said senior author Dr. Matthew Ellis, professor of oncology at Baylor College of Medicine. "The tumor's DNA is released into the human bloodstream, and we were able to determine the presence of the mutation in blood samples from the patients. Importantly the circulating tumor DNA results were highly concordant with the tumor sequencing results, and they were much easier to determine. Notably, the blood test was sensitive enough that we could use it as a tool to determine eligibility for the clinical trial. A circulating tumor DNA-based blood test also could therefore be potentially used to monitor tumor progression and to determine whether patients are responding or not to treatment after just one month of therapy."
The study was published in the July 5, 2017, online edition of the journal Clinical Cancer Research.
Related Links:
Baylor College of Medicine
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans